$23.84
+1.71%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$23.51
From 52W high−30.15%
Volume295829.00
Market cap$280.20M
P/E (TTM)—
P/S (TTM)24.3x
Div yield—
Key dataOct 19, 2026
Open
$23.51
From 52W high
−30.15%
Volume
295829.00
Market cap
$280.20M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
47.2
MomentumView details →
1D Return
+1.71%
YTD Return
+4.65%
SummaryUpdated Jun 1, 2026
Surrozen, Inc. (NASDAQ:SRZN) is a biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in January 2021 and focuses on discovering and developing drug candidates that selectively modulate the Wnt signaling pathway for tissue repair and regeneration. Surrozen represents a specialized approach to regenerative medicine, targeting various organ systems including the liver, intestines, retina, and other tissues through its proprietary antibody-based therapeutics.
Similar companies
Latest newsMore news →
Surrozen announced that the FDA clearance milestone triggers the second closing of its March 2025 private placement, expected to provide approximately $95.1 million in gross proceeds.18d agoThe FDA cleared Surrozen's Investigational New Drug application for SZN-8141 for the treatment of diabetic macular edema, allowing the company to advance the program into clinical development.18d agoSurrozen submitted an Investigational New Drug application to the U.S. Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema.42d ago